Carol Hutchinson

Dr. Carol Hutchinson

Mahidol University, Bangkok, Krung Thep Maha Nakhon, Thailand
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2004 in British Journal of Nutrition
Verified
Journal Article
Open access
PDF file
MLMiranda C E Lomer
Miranda C E Lomer
Carol HutchinsonCarol Hutchinson
Carol Hutchinson
SVSara Volkert
Sara Volkert
SGSimon M. Greenfield
Simon M. Greenfield
ACAdrian Catterall
Adrian Catterall
JPJonathan J. Powell
Jonathan J. Powell
Dietary microparticles are non-biological, bacterial-sized particles. Endogenous sources are derived from intestinal Ca and phosphate secretion. Exogenous sources are mainly titanium dioxide (TiO2) and mixed silicates (Psil); they are resistant to degradation and accumulate in human Peyer's patch macrophages and there is some evidence that they exacerbate inflammation in Crohn's disease (CD). However, whether their intake differs between those with and without CD has not been studied. We aimed to identify dietary microparticle sources and intakes in subjects with and without CD. Patients with inactive CD and matched general practice-based controls (ninety-one per group) completed 7d food diaries. Intake data for dietary fibre and sucrose were compared as positive controls. All foods, pharmaceuticals and toothpastes were examined for microparticle content, and intakes of Ca and exogenous microparticles were compared between the two groups. Dietary intakes were significantly different between cases and controls for dietary fibre (12 (SD 5)v. 14 (sd 5) g/d;P=0.001) and sucrose (52 (sd 27)v. 45 (sd 18) g/d;P=0·04) but not for Ca. Estimated median TiO2and Psil intakes (2·5 and 35mg/individual per d respectively, totalling 1012–1013microparticles/individual per d) were broadly similar toper capitaestimates and while there was wide variation in intakes between individuals there was no significant difference between subjects with CD and controls. Hence, if exposure to microparticles is associated with the inflammation of CD, then the present study rules out excess intake as the problem. Nonetheless, microparticle-containing foods have now been identified which allows a low-microparticle diet to be further assessed in CD.

7 March 2007 in Gut
Verified
Journal Article
Open access
PDF file
Carol HutchinsonCarol Hutchinson
Carol Hutchinson
CGCatherine A Geissler
Catherine A Geissler
JPJonathan J Powell
Jonathan J Powell
ABAdrian Bomford
Adrian Bomford
Background and Aims: During the long-term treatment of patients with hereditary haemochromatosis (HH) the authors observed that proton pump inhibitors (PPI) reduced the requirement for maintenance phlebotomy. Gastric acid plays a crucial role in non-haem iron absorption and the authors performed a case review and intervention study to investigate if PPI-induced suppression of gastric acid would reduce dietary iron absorption in C282Y homozygous patients. Methods: Phlebotomy requirements to keep serum ferritin ∼50 μg/l before (mean 6.1 (SE 0.6) years) and during (3.8 (0.9) years) administration of a PPI were evaluated in seven patients and a post-prandial study was performed to determine whether PPIs reduce absorption of non-haem iron (14.5 mg) from a test meal in a further 14 phlebotomised patients with normal iron stores. Results: There was a significant reduction (p<0.001) in the volume of blood removed annually before (2.5 (0.25) l) and while taking (0.5 (0.25) l) a PPI. Administration of a PPI for 7d suppressed absorption of non-haem iron from the meal as shown by a significant reduction (all p<0.01) in: area under the serum curve (2145 (374) versus 1059 (219)), % recovery of administered iron at peak serum iron (20.5 (3.2) versus 11.0 (2.0)%) and peak serum iron (13.6 (2.4) vs 6.1 (1.2) µmol/l) (all values are before vs during PPI). Conclusions: Administration of a PPI to patients with HH can inhibit the absorption of non-haem iron from a test meal and the habitual diet.

16 February 2016 in European Journal of Nutrition
Verified
Journal Article
Closed access
PDF file
Carol HutchinsonCarol Hutchinson
Carol Hutchinson

3 November 2004 in European Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
Carol HutchinsonCarol Hutchinson
Carol Hutchinson
WAW. Al‐Ashgar
W. Al‐Ashgar
DLD. Y. Liu
D. Y. Liu
RHRobert Charles Hider
Robert Charles Hider
JPJ. J. Powell
J. J. Powell
CGC. A. Geissler
C. A. Geissler

1 January 2004 in British Journal of Nutrition
Verified
Journal Article
Closed access
PDF file
MLMiranda C E Lomer
Miranda C E Lomer
KKKamelia Kodjabashia
Kamelia Kodjabashia
Carol HutchinsonCarol Hutchinson
Carol Hutchinson
SGSimon M. Greenfield
Simon M. Greenfield
RTRichard P. H. Thompson
Richard P. H. Thompson
JPJonathan J. Powell
Jonathan J. Powell
Patients with Crohn's disease (CD) often experience Fe deficiency (ID) and frequently alter their diet to relieve abdominal symptoms. The present study set out to assess whether patients with CD have dietary habits that lead to low Fe intakes and/or reduced bioavailable Fe compared with control subjects. Patients with asymptomatic CD were matched to controls (n91/group). Dietary intakes of Fe and contributions from different food groups were compared using a 7 d food diary. Promoters and inhibitors of non-haem Fe absorption were investigated and a recently published algorithm was applied to assess bioavailable Fe. Fewer patients than controls met the reference nutrient intake for Fe (32 % CD patientsv. 42 % controls). Overall, patients had significantly lower mean Fe intakes (by 2·3 mg/d) and Fe density (by 0·26 mg/MJ (1·1 mg/1000 kcal)) compared with controls (bothP<0·001). Differences were mainly due to a preference among CD patients for low-fibre non-Fe fortified cereals, particularly breakfast cereals. In particular, control subjects had higher Fe intakes than matched CD subjects for men (P<0·001) and women less than 50 years (P=0·03). Intakes of both ascorbic acid (P<0·001) and phytic acid (P<0·01), but not animal tissue (P=1·0), were lower in patients with CD, but these had no overall effect on the predicted percentage of bioavailable Fe. Thus total bioavailable Fe was reduced in patients with CD due to lower intakes (P<0·01). Dietary Fe intakes are low in CD patients, which may contribute to an increased risk of ID and anaemia. Changing dietary advice may compromise perceived symptoms of the disease so the need for Fe supplementation should be carefully considered.

14 July 2010 in European Journal of Clinical Nutrition
Verified
Journal Article
Open access
PDF file
Carol HutchinsonCarol Hutchinson
Carol Hutchinson
ABA Bomford
A Bomford
CGC A Geissler
C A Geissler
Milk thistle contains silybin, which is a potential iron chelator. We aimed to determine whether silybin reduced iron absorption in patients with hereditary haemochromatosis. In this crossover study, on three separate occasions, 10 patients who were homozygous for the C282Y mutation in the HFE gene (and fully treated) consumed a vegetarian meal containing 13.9 mg iron with: 200 ml water; 200 ml water and 140 mg silybin (Legalon Forte); or 200 ml tea. Blood was drawn once before, then 0.5, 1, 2, 3 and 4 h after the meal. Consumption of silybin with a meal resulted in a reduction in the postprandial increase in serum iron (AUC±s.e.) compared with water (silybin 1726.6±346.8 versus water 2988.8±167; P<0.05) and tea (silybin 1726.6±346.8 versus tea 2099.3±223.3; P<0.05). In conclusion, silybin has the potential to reduce iron absorption, and this deserves further investigation, as silybin could be an adjunct in the treatment of haemochromatosis.